<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111314</url>
  </required_header>
  <id_info>
    <org_study_id>21-004930</org_study_id>
    <secondary_id>NCI-2021-11290</secondary_id>
    <secondary_id>21-004930</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT05111314</nct_id>
  </id_info>
  <brief_title>Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma</brief_title>
  <official_title>Intraindividual Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMAPET/CT in Patients With HCC: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 0/1 study evaluates intraarterial administration of gallium Ga 68 gozetotide&#xD;
      (68Ga-PSMA) for the detection of prostate-specific membrane antigen (PSMA) positive liver&#xD;
      cancer by positron emission tomography (PET)/computed tomography (CT). 68Ga-PSMA is an&#xD;
      imaging agent used with PET/CT scans to locate PSMA positive lesions. This study evaluates&#xD;
      intraarterial administration of this agent, compared to intravenous administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the tumor radiotracer uptake (first pass effect or regional advantage) of&#xD;
      direct hepatic intraarterial (I.A.) versus systemic intravenous (I.V.) 68Ga-PSMA in patients&#xD;
      with PSMA+ hepatocellular carcinoma (HCC) by PET/CT.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergoing clinically indicated hepatic artery embolization will receive 68Ga-PSMA&#xD;
      intraarterially (IA) over 5 minutes. After 60-90 minutes, patients undergo PET/CT scan over 1&#xD;
      hour.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 6, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraindividual intralesional difference in maximum standardized uptake value (SUVmax)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Intraindividual intralesional difference in maximum standardized uptake value (SUVmax) will be evaluated as fold change and absolute difference for a given lesion between intra-arterially (I.A.) and intravenous (I.V.) prostate-specific membrane antigen (PSMA) positron emission tomography (PET). Qualitative evaluation assesses the intensity of PSMA uptake in hepatic lesions, graded as follows: grade 1: uptake &lt; normal liver; grade 2: uptake = normal liver; grade 3: uptake &gt; normal liver; grade 4: uptake &gt; spleen or kidneys. Semi-quantitative analysis is undertaken by calculating intraindividual difference in SUVmax for each lesion between I.A. and I.V. PSMA PET followed by a two-sided one sample t-test. Maximum and mean standardized uptake value (SUVmax, SUVmean, SUVmin) of the lesion(s), and SUVmax of the background liver are noted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraindividual intralesional differences in tumor to background (TBR) of SUVmax</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>For each lesion, tumor-to-liver background ratio (TBR) of SUVmax will be calculated and the intraindividual intralesional difference in TBR of SUVmax will be compared on a lesion basis between I.A. and I.V. PSMA PET.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in PSMA uptake measured by SUVmax (fold change, absolute difference) in the kidneys, spleen and salivary glands between I.A. and I.V. PSMA PET.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>SUVmax will be measured for the kidneys, spleen and salivary glands and the difference in PSMA uptake measured by SUVmax (fold change, absolute difference) in the kidneys, spleen and salivary glands will be compared between I.A. and I.V. PSMA PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (embolization, 68Ga-PSMA, PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing clinically indicated hepatic artery embolization will receive 68Ga-PSMA intraarterially (IA) over 5 minutes. After 60-90 minutes, patients undergo PET/CT scan over 1 hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gallium Ga 68 Gozetotide</intervention_name>
    <description>Given IA</description>
    <arm_group_label>Diagnostic (embolization, 68Ga-PSMA, PET/CT)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68Ga)Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-DKFZ-PSMA-11</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>68Ga-PSMA-HBED-CC</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga PSMA</other_name>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>GA-68 PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium Ga 68-labeled PSMA-11</other_name>
    <other_name>GALLIUM GA-68 GOZETOTIDE</other_name>
    <other_name>Gallium-68 PSMA</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>GaPSMA</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatic Artery Embolization</intervention_name>
    <description>Undergo hepatic artery embolization</description>
    <arm_group_label>Diagnostic (embolization, 68Ga-PSMA, PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography and Computed Tomography Scan</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Diagnostic (embolization, 68Ga-PSMA, PET/CT)</arm_group_label>
    <other_name>PET-CT Scan</other_name>
    <other_name>PET/CT SCAN</other_name>
    <other_name>Positron Emission Tomography/Computed Tomography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with either an imaging diagnosis of HCC by CT or magnetic resonance imaging&#xD;
             (MRI) (Liver Imaging and Reporting Data System 5 [LI-RADS 5]) confirmed by a&#xD;
             board-certified abdominal radiologist, or with biopsy-proven HCC&#xD;
&#xD;
          -  Already enrolled in ongoing Transform the Practice or Department of Defense 68Ga-PSMA&#xD;
             studies&#xD;
&#xD;
          -  PSMA avid HCC detected by 68Ga-PSMA PET/CT after intravenous administration of&#xD;
             68Ga-PSMA confirmed by a board certified nuclear radiologist&#xD;
&#xD;
          -  Undergoing planned hepatic artery embolization (HAE) per standard clinical care&#xD;
&#xD;
          -  Male or female with age greater than 18 years, with the capacity and willingness to&#xD;
             provide a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects requiring emergent surgery for a ruptured/bleeding HCC&#xD;
&#xD;
          -  Pregnant and/or breast-feeding subjects. A negative pregnancy test within 48 hours of&#xD;
             the PET scan&#xD;
&#xD;
          -  Subjects with higher than the weight/size limitations of PET/CT scanner&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott M Thompson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Clincial Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Scott M. Thompson, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Scott M. Thompson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

